CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R01 Clinical Trial Not Allowed)
- · 24d
- $300,000
- 5
- May 4, 2026
Official announcement on nih_guide+grants_gov · opens the funder's page. Always confirm dates there.
Summary
The civilian chemical threat spectrum includes chemical warfare agents, toxic industrial chemicals and materials, pharmaceutical-based agents, and others that have been collectively identified by the United States Government (USG) as Chemicals of Concern (CoCs). […]
Other topics in this solicitation
Limited Competition: Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) (P30 - Clinical Trial Not Allowed)
NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)
NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)
Seed Instrumentation Support (SIS) Program (S10 Clinical Trial Not Allowed)
$400k
Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)
Biomedical Technology Optimization and Dissemination Center (BTOD) (RM1 - Clinical Trial Not Allowed)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
The rest of this announcement — free with an account
- The full announcement text, not the first two sentences
- All 3 review criteria reviewers score this against, extracted from this announcement
- Whether you are eligible — career stage, institution type, and the windows that close before the deadline does
- What similar funded projects received, from 219,000 past awards
More from National Institutes of Health
Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)
$250k
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
$350k